Purchase this article with an account.
A. Deudon Combe; 12 Months Follow-Up of Combined Therapy With Intravitreal Injections of Ranibizumab +/- Triamcinolone Associated With Photodynamic Therapy Reduced Fluence (pdt) in Patients With Exsudative Age-Related Macular Degeneration (wamd). Invest. Ophthalmol. Vis. Sci. 2010;51(13):99.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the mean 12 months efficacy (VA assessment) in patients receiving combined therapy with intravitreal injections (IVT) of ranibizumab +/- triamcinolone associated with photodynamic therapy reduced fluence (PDT).
Non-comparative retrospective analysis on 60 patients with exsudative age-related macular degeneration (wAMD) treated at baseline with a tritherapy associating PDT reduced-fluence (300mW/cm²) and the week after Intravitreal injections (IVT) of Ranibizumab 0.5mg + triamcinolone 4mg. Patients were retreated as needed with a combined therapy : PDT + Ranibizumab +/- triamcinolone according to retreatment criteria mainly based on OCT and FA examinations.
On the 60 patients 35 (58.3%) has received tritherapy cycles after the initial treatment. the mean number of treatments was 2.48 during the 12 months follow-up. The mean VA at baseline was 28.35 letters and the mean VA change versus baseline was +2.1 letters. six patients (10%) gained more than 15 letters, 33 patients (55%) gained more than 0 letters and 2 patients (3.3%) lost more than 15 letters. The treatment was generaly well tolerated with no serious adverse events. Only one patient presented a pseudo-uveitis associated with intraocular pressure increase after tritherapy.
this approach combining 3 treatments such as PDT -reduced fluence + Ranibizumab + /- triamcinolone showed a trend to vision stabilization with less treatments cycles despite the low baseline VA of patients included in this retrospective analysis. This approach should be further evaluated in prospective clinical trials.
This PDF is available to Subscribers Only